336 related articles for article (PubMed ID: 26607741)
21. Immune and Inflammatory Cells in Thyroid Cancer Microenvironment.
Ferrari SM; Fallahi P; Galdiero MR; Ruffilli I; Elia G; Ragusa F; Paparo SR; Patrizio A; Mazzi V; Varricchi G; Marone G; Antonelli A
Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31500315
[TBL] [Abstract][Full Text] [Related]
22. CXCL13 shapes immunoactive tumor microenvironment and enhances the efficacy of PD-1 checkpoint blockade in high-grade serous ovarian cancer.
Yang M; Lu J; Zhang G; Wang Y; He M; Xu Q; Xu C; Liu H
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33452206
[TBL] [Abstract][Full Text] [Related]
23. γδ T Cells in Tumor Microenvironment.
Imbert C; Olive D
Adv Exp Med Biol; 2020; 1273():91-104. PubMed ID: 33119877
[TBL] [Abstract][Full Text] [Related]
24. Pushing Past the Blockade: Advancements in T Cell-Based Cancer Immunotherapies.
Waibl Polania J; Lerner EC; Wilkinson DS; Hoyt-Miggelbrink A; Fecci PE
Front Immunol; 2021; 12():777073. PubMed ID: 34868044
[TBL] [Abstract][Full Text] [Related]
25. Malignant pleural mesothelioma immune microenvironment and checkpoint expression: correlation with clinical-pathological features and intratumor heterogeneity over time.
Pasello G; Zago G; Lunardi F; Urso L; Kern I; Vlacic G; Grosso F; Mencoboni M; Ceresoli GL; Schiavon M; Pezzuto F; Pavan A; Vuljan SE; Del Bianco P; Conte P; Rea F; Calabrese F
Ann Oncol; 2018 May; 29(5):1258-1265. PubMed ID: 29514216
[TBL] [Abstract][Full Text] [Related]
26. Clinical significance of tumor-infiltrating lymphocytes in breast cancer.
Stanton SE; Disis ML
J Immunother Cancer; 2016; 4():59. PubMed ID: 27777769
[TBL] [Abstract][Full Text] [Related]
27. Targeting Checkpoint Receptors and Molecules for Therapeutic Modulation of Natural Killer Cells.
Kim N; Kim HS
Front Immunol; 2018; 9():2041. PubMed ID: 30250471
[TBL] [Abstract][Full Text] [Related]
28. Infiltration by Intratumor and Stromal CD8 and CD68 in Cervical Cancer.
Dimitrova P; Vasileva-Slaveva M; Shivarov V; Hasan I; Yordanov A
Medicina (Kaunas); 2023 Apr; 59(4):. PubMed ID: 37109686
[No Abstract] [Full Text] [Related]
29. The reciprocal function and regulation of tumor vessels and immune cells offers new therapeutic opportunities in cancer.
Missiaen R; Mazzone M; Bergers G
Semin Cancer Biol; 2018 Oct; 52(Pt 2):107-116. PubMed ID: 29935312
[TBL] [Abstract][Full Text] [Related]
30. CD8
Farhood B; Najafi M; Mortezaee K
J Cell Physiol; 2019 Jun; 234(6):8509-8521. PubMed ID: 30520029
[TBL] [Abstract][Full Text] [Related]
31. Intratumoral CXCL13
Dai S; Zeng H; Liu Z; Jin K; Jiang W; Wang Z; Lin Z; Xiong Y; Wang J; Chang Y; Bai Q; Xia Y; Liu L; Zhu Y; Xu L; Qu Y; Guo J; Xu J
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33589528
[TBL] [Abstract][Full Text] [Related]
32. Overview of Basic Immunology for Clinical Investigators.
Stephen B; Hajjar J
Adv Exp Med Biol; 2017; 995():1-31. PubMed ID: 28321810
[TBL] [Abstract][Full Text] [Related]
33. The immune microenvironment of HPV-positive and HPV-negative oropharyngeal squamous cell carcinoma: a multiparametric quantitative and spatial analysis unveils a rationale to target treatment-naïve tumors with immune checkpoint inhibitors.
Tosi A; Parisatto B; Menegaldo A; Spinato G; Guido M; Del Mistro A; Bussani R; Zanconati F; Tofanelli M; Tirelli G; Boscolo-Rizzo P; Rosato A
J Exp Clin Cancer Res; 2022 Sep; 41(1):279. PubMed ID: 36123711
[TBL] [Abstract][Full Text] [Related]
34. Tumor Microenvironment and Nitric Oxide: Concepts and Mechanisms.
Vedenko A; Panara K; Goldstein G; Ramasamy R; Arora H
Adv Exp Med Biol; 2020; 1277():143-158. PubMed ID: 33119871
[TBL] [Abstract][Full Text] [Related]
35. Role of lymphocytes, macrophages and immune receptors in suppression of tumor immunity.
Singh A; Anang V; Kumari K; Kottarath SK; Verma C
Prog Mol Biol Transl Sci; 2023; 194():269-310. PubMed ID: 36631195
[TBL] [Abstract][Full Text] [Related]
36. Interleukin-4 induced 1-mediated resistance to an immune checkpoint inhibitor through suppression of CD8
Hirose S; Mashima T; Yuan X; Yamashita M; Kitano S; Torii S; Migita T; Seimiya H
Cancer Sci; 2024 Mar; 115(3):791-803. PubMed ID: 38258342
[TBL] [Abstract][Full Text] [Related]
37. Innate Lymphoid Cells: Expression of PD-1 and Other Checkpoints in Normal and Pathological Conditions.
Mariotti FR; Quatrini L; Munari E; Vacca P; Moretta L
Front Immunol; 2019; 10():910. PubMed ID: 31105707
[TBL] [Abstract][Full Text] [Related]
38. Identification and verification of PTPN3 as a novel biomarker in predicting cancer prognosis, immunity, and immunotherapeutic efficacy.
Zhou Z; Lin Z; Wang M; Wang L; Ji Y; Yang J; Yang Y; Zhu G; Liu T
Eur J Med Res; 2024 Jan; 29(1):12. PubMed ID: 38173048
[TBL] [Abstract][Full Text] [Related]
39. The immune checkpoint adenosine 2A receptor is associated with aggressive clinical outcomes and reflects an immunosuppressive tumor microenvironment in human breast cancer.
Zohair B; Chraa D; Rezouki I; Benthami H; Razzouki I; Elkarroumi M; Olive D; Karkouri M; Badou A
Front Immunol; 2023; 14():1201632. PubMed ID: 37753093
[TBL] [Abstract][Full Text] [Related]
40. Comprehensive analysis of 33 human cancers reveals clinical implications and immunotherapeutic value of the solute carrier family 35 member A2.
Xu S; Chen X; Fang J; Chu H; Fang S; Zeng L; Ma H; Zhang T; Chen Y; Wang T; Zhang X; Shen T; Zheng Y; Xu D; Lu Z; Pan Y; Liu Y
Front Immunol; 2023; 14():1155182. PubMed ID: 37275857
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
